Viewing nowCombinationTubero Tablet 30/10 mg (Pimasartan Potassium, Rosuvastatin)
Fimasartan Potassium Trihydrate Granules 75mg · Rosuvastatin Calcium 10.4mg
Tablet · Prescription medication · Combination
Boryung Pharmaceutical Co., Ltd.

MFDS item code 201605336 · Approved 2016.08.31 · Insurance code 641906550
Treatment of hypertension; improves dyslipidemia; inhibits the progression of atherosclerosis and reduces cardiovascular disease risk
This medication is used for patients who require the combined administration of two drugs, Pimasartan and Rosuvastatin. Pimasartan is primarily used for the treatment of essential hypertension. Rosuvastatin is effective for dyslipidemia such as hypercholesterolemia and is used as an adjunct when dietary control and exercise alone cannot manage the condition. It is also helpful in the treatment of patients with homozygous familial hypercholesterolemia or primary dysbetalipoproteinemia. Rosuvastatin lowers cholesterol levels in patients with hypercholesterolemia and is used to delay the progression of atherosclerosis and reduce the risk of cardiovascular disease. Therefore, this medication is suitable for patients with both hypertension and dyslipidemia, effectively improving blood pressure and cholesterol levels.
This medicine is for adults only. The dose should be individualized for each patient based on the efficacy and tolerability of each component, fimasartan and rosuvastatin. ○ Fimasartan 1. Adults The recommended dose of this medicine is 30~60 mg once daily, with or without food. If blood pressure is not adequately controlled at this dose, the dose may be increased to 120 mg once daily. If possible, it is recommended that the medicine be taken at the same time each day (e.g., in the morning). The blood pressure-lowering effect appears within 2 weeks after starting treatment and reaches its maximum after approximately 8 weeks~12 weeks. 2. Older adults No initial dose adjustment is required in older adults aged 70 years or younger. 3. Patients with renal impairment No dose adjustment is required in patients with mild~moderate renal impairment (creatinine clearance 30~80 mL/min). In patients with severe renal impairment (creatinine clearance < 30 mL/min), however, treatment should be initiated at 30 mg once daily, and the dose should not exceed 60 mg per day. 4. Patients with hepatic impairment No dose adjustment is required in patients with mild hepatic impairment. This medicine should not be administered to patients with moderate~severe hepatic impairment. 5. Patients with reduced effective circulating blood volume (e.g., patients taking high doses of diuretics) For patients at high risk of hypotension, such as those with reduced effective circulating blood volume, an initial dose of 30 mg once daily is recommended. ○ Rosuvastatin 1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medicine and continue it throughout the treatment period. This medicine may be taken at any time of day, with or without food. The initial dose is 5 mg once daily. If a greater reduction in LDL cholesterol is needed, the dose may be adjusted to a maintenance dose. The maintenance dose is 10 mg once daily, which controls the condition in most patients. The maintenance dose should be adjusted as appropriate at intervals of 4 weeks or longer according to LDL cholesterol levels, treatment goals, and the patient's response; the dose may be increased up to a maximum of 20 mg per day. 2. Older adults No dose adjustment is required. 3. Patients with renal impairment No dose adjustment is required in patients with mild or moderate renal impairment. This medicine should not be administered to patients with severe renal impairment. Particular caution is required when administering 20mg of this medicine to patients with moderate renal impairment. 4. Patients with hepatic impairment Systemic exposure to rosuvastatin did not increase in patients with a Child-Pugh score of 7 or less, but it increased in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. This medicine should not be administered to patients with active liver disease. 5. Race Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 mg. Administration of the 40 mg dose is contraindicated. 6. Patients predisposed to myopathy The recommended initial dose for patients predisposed to myopathy is 5 mg. Administration of the 40 mg dose of this medicine is contraindicated in some of these patients. Patients taking fimasartan and rosuvastatin concomitantly may switch to this medicine (a combination product containing the same amounts of each active ingredient) for convenience of administration.
This medication can cause serious harm to the fetus and newborn if taken during pregnancy, especially in the second and third trimesters; therefore, it should be discontinued immediately if pregnancy is confirmed. Patients who are allergic to the ingredients of this medication, women who are pregnant or may become pregnant, nursing mothers, and women of childbearing age who are not using appropriate contraception should not take this medication. This medication should not be used in patients with moderate to severe liver impairment, patients with bile duct obstruction, patients with muscle disorders, patients with severe renal impairment, and patients taking certain medications. Patients with low blood volume or sodium, patients with impaired kidney function, and patients with heart valve disease should be especially cautious when taking this medication and adjust the dosage under physician supervision. This medication can cause serious muscle-related side effects such as myalgia or myopathy, and rarely rhabdomyolysis, so if symptoms of muscle pain or weakness occur, patients should inform medical personnel immediately. Additionally, this medication may affect liver function, so it is important to have regular liver function tests before and during the course of treatment. There may be interactions with other medications, so if the patient is taking current medications, they must inform their healthcare provider, especially when taken with potassium-sparing diuretics, lithium, non-steroidal anti-inflammatory drugs, etc. There may be symptoms such as dizziness or drowsiness when driving or operating machinery, so caution is advised. This medication has not been established for safety and efficacy in children and adolescents under 18, so it is advisable not to use it in this population. In case of overdose, appropriate treatment based on symptoms is necessary, and especially symptoms of hypotension or liver function abnormalities may occur, so patients should consult medical personnel immediately. Finally, this medication should be stored out of reach of children and should not be transferred to other containers.
Dyspepsia, nausea, fever, hepatitis, headache, dizziness, upper abdominal pain, esophagitis, gastroenteritis, nasopharyngitis, tonsillitis, upper respiratory infection, elevated ALT, elevated γ-GTP, elevated liver enzymes, increased white blood cell count, urination disorders, increased urination, cough, hyperkalemia, arthralgia, insomnia, pruritus, syncope, sedation, migraine, vomiting, weakness, foreign body sensation, decreased platelet count, increased serum creatine phosphokinase, muscle contractions, musculoskeletal stiffness, facial flushing, flushing, erectile dysfunction, hypersensitivity reactions including angioedema, constipation, abdominal pain, pancreatitis, rash, urticaria, myalgia, myopathy, rhabdomyolysis, weakness, polyneuropathy, amnesia, peripheral neuropathy, diarrhea, thrombocytopenia, jaundice, Stevens-Johnson syndrome, drug reaction with eosinophilia and systemic symptoms, lupus-like syndrome, muscle rupture, immune-mediated necrotizing myopathy, hematuria, edema, depression, sleep disturbances, sexual dysfunction, gynecomastia, fatal and non-fatal liver failure, cognitive impairment, severe muscle weakness, ocular myasthenia, contusion, acute pancreatitis, intestinal obstruction, hemorrhagic duodenal ulcer, appendicitis, hemorrhoids, abdominal pain, intracranial hemorrhage, transient ischemic attack, atherosclerosis, exacerbation of cerebral infarction, cerebral hemorrhage, liver cancer, colon carcinoma, neoplasm of unspecified type, cervical cancer, prostate cancer, acute renal failure, chronic renal failure, kidney stones, pyelonephritis, urinary incontinence, rhinitis, interstitial pneumonia, pharyngitis, pneumonia, lung disease, death, worsening of low back pain, osteoarthritis, arthropathy, hypoglycemia, pulmonary embolism, purpura, bradycardia, atrial fibrillation, heart failure, increased blood pressure, acute hepatitis, benign pituitary neoplasm, otitis media, uterine prolapse, recurrent cancer, chest pain, low back pain, edema, limb pain, peripheral edema, facial edema, fatigue, fever, neck/shoulder pain, fracture, osteoporosis, myalgia, pharyngitis, upper respiratory infection, sputum, rhinitis, epistaxis, bronchitis, sensory disturbances, numbness, tremor, hypertonia, anxiety, memory impairment, loss of appetite, gastroesophageal reflux, gastritis, constipation, functional gastrointestinal disorder, gastroenteritis, increased urination, urinary incontinence, kidney stones, chronic renal failure, difficulty urinating, hyperlipidemia, dyslipidemia, hypoglycemia, cerebral infarction, shingles, visual disturbances, tachycardia, increased blood pressure, purpura, fatty liver, localized inflammation, soft tissue inflammation, lymphadenopathy, lacerations of unspecified type, deviated septum, surgical intervention, postoperative pain, heat intolerance, falls, postoperative pain, allergy, chills, nasal polyps, edema, peripheral edema, pneumonia, lung disease, hemoptysis, exacerbation of rhinitis, asthma, pulmonary granuloma, abnormal chest X-ray findings, pharyngitis, sputum, bronchitis, hypercholesterolemia, diabetes, hypertriglyceridemia, thirst, worsening of diabetes, calcinosis, hyponatremia, gout, eye pain, retinal disease, glaucoma, cataracts, double vision, floaters, uveitis, exacerbation of chronic renal failure, cystitis, urinary tract infection, increased BUN, acute renal failure, pyelonephritis, otitis media, fungal infection, abscess, bacterial infection, genital herpes, cold sores, shingles, myeloproliferative disease, exacerbation of anemia, iron deficiency anemia, tinnitus, hearing impairment, hearing loss, pelvic inflammatory disease, vaginitis, benign prostatic hyperplasia, scrotal pain, blood pressure fluctuations
Not everyone experiences these, and they can vary from person to person.
Store this medication in a tightly sealed container to prevent air or moisture from entering, and keep it at room temperature, between 1 to 30 degrees Celsius. Proper storage will help maintain the effectiveness of the medication.
Light green, convex, octagonal film-coated tablets
30 tablets/box [10 tablets/PTP packaging × 3], 100 tablets/box [10 tablets/PTP packaging × 10], 30 tablets/box [10 tablets/Alu-Alu packaging × 3], 100 tablets/box [10 tablets/Alu-Alu packaging × 10]
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowCombinationFimasartan Potassium Trihydrate Granules 75mg · Rosuvastatin Calcium 10.4mg
Tablet · Prescription medication · Combination
Boryung Pharmaceutical Co., Ltd.
CombinationFimasartan Potassium Trihydrate Granules 150mg · Rosuvastatin Calcium 10.4mg
Tablet · Prescription medication · Combination
Boryung Co., Ltd.
CombinationFimasartan Potassium Trihydrate Granules 150mg · Rosuvastatin Calcium 5.2mg
Tablet · Prescription medication · Combination
Boryung Pharmaceutical Co., Ltd.
CombinationFimasartan Potassium Trihydrate Granules 300mg · Rosuvastatin Calcium 20.8mg
Tablet · Prescription medication · Combination
Boryung Pharmaceutical Co., Ltd.
CombinationFimasartan Potassium Trihydrate Granules 75mg · Rosuvastatin Calcium 5.2mg
Tablet · Prescription medication · Combination
Boryung Pharmaceutical Co., Ltd.
Fimasartan Potassium Trihydrate Granules 75mg · Rosuvastatin Calcium 10.4mg
Tablet · Prescription medication · Combination
Boryung Biopharma Co., Ltd.
Fimasartan Potassium Trihydrate Granules 75mg · Rosuvastatin Calcium 5.2mg
Tablet · Prescription medication · Combination
Boryung Biopharma Co., Ltd.
Fimasartan Potassium Trihydrate Granules 150mg · Rosuvastatin Calcium 10.4mg
Tablet · Prescription medication · Combination
Boryung Biopharma Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.